(Q35473061)

8 August 2017

1 reference

title

Tamoxifen in axillary node--negative breast cancer: multisystem benefits and risks (English)

1 reference

8 August 2017

1 reference

Love RR

1

1 reference

8 August 2017

language of work or name

1 reference

1 January 1992

1 reference

8 August 2017

1 reference

8 August 2017

volume

10

1 reference

8 August 2017

issue

6

1 reference

8 August 2017

page(s)

587-593

1 reference

Projections of the breast cancer burden to U.S. women: 1990-2000.

8 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F07357909209024821

Evaluation of the increase in breast cancer incidence in relation to mammography use.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209024821

Assessing the risk of recurrence in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209024821

A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209024821

Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209024821

Effect of tamoxifen on serum insulinlike growth factor I levels in stage I breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209024821

Should all patients with node-negative breast cancer receive adjuvant therapy? Identifying additional subsets of low-risk patients who are highly curable by surgery alone

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209024821

Interobserver reproducibility of histopathological features in stage II breast cancer. An ECOG study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209024821

Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209024821

Tumor promotion as a target for estrogen/antiestrogen effects in rat hepatocarcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209024821

Synthetic estrogens and tamoxifen as promoters of hepatocarcinogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209024821

Epidemiologic data on exogenous hormones and hepatocellular carcinoma and selected other cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209024821

Antiestrogen chemoprevention of breast cancer: critical issues and research

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209024821

Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209024821

Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209024821

10.3109/07357909209024821

21 January 2018

Identifiers

DOI

1 reference

8 August 2017

1 reference